Observational studyEpilepsia open2025
Effectiveness and safety of early add-on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV-add study.
Observational study in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- First-year Experience with Brivaracetam in Japan: Real-world Data from Juntendo Epilepsy Center.Neurologia medico-chirurgica · 2026Article
- Effectiveness and safety of early add-on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV-add study.Epilepsia open · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo evaluate the effectiveness and safety of brivaracetam (BRV) as an add-on therapy in patients with focal onset seizures who did not achieve seizure freedom with antiseizure medication (ASM) monotherapy in routine clinical practice.
methodsThis was a retrospective, observational, multicenter study conducted across 17 neurology centers in Spain. We evaluated adult patients with focal onset epilepsy who had inadequate seizure control after at least 3 months of ASM monotherapy and were treated with dual therapy, combining BRV with their previous ASM, with the intention of maintaining this treatment for at least 6 months. Data were collected from medical records on seizure frequency, ASM doses, and adverse events (AEs), taking into account the end of this 6-month period of dual therapy. The primary efficacy outcomes were the proportion of patients achieving ≥50% reduction in seizure frequency and those achieving seizure freedom. Safety outcomes included the incidence of treatment-related AEs.
resultsA total of 195 patients (mean age: 43.2 years; 52.3% male; mean disease duration: 11.5 years) were included in the study. The main location of epilepsy was identified (53.8%) as the frontal lobe (27.7%). The mean number of seizures during the last 3 months of ASM monotherapy was 12.1 (SD 39.5), which decreased to 6.4 (SD 21.2) after 6 months of BRV add-on therapy. A ≥ 50% reduction in seizure frequency was achieved by 90.8% of patients, while 49.7% reached seizure freedom. The most common AEs were related to the central nervous system, reported by 22.1% of patients, with a treatment discontinuation rate due to AEs of 12.8%. SIGNIFICANCE: BRV as an add-on therapy is effective in reducing seizure frequency and is well-tolerated in patients with focal onset seizures. This study supports the use of BRV as an add-on option in patients who do not achieve adequate seizure control with ASM monotherapy. PLAIN LANGUAGE SUMMARY: This study evaluated how effective and safe brivaracetam (BRV) is when added to another medication for patients with focal onset seizures. The results showed that adding BRV helped many patients reduce the number of seizures, and some patients stopped having seizures completely. Side effects were generally mild.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.